Cognetivity Neurosciences well placed to help individuals and health services deal with unprecedented challenge of Covid-19 as global demand for telemedicine surges
VANCOUVER, April 1, 2020 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) is continuing to monitor the development of the Covid-19 pandemic worldwide and expects to be able to deliver its technology to mitigate the strain placed by the crisis on both healthcare services and self-isolating individuals. The company’s digital assessment capabilities are well matched to the burgeoning importance of telemedicine and telecare in the UK and beyond.
As the elderly are forced to self-isolate and mental health services are curbed in an effort to divert resources, waiting lists for dementia assessment services are forecast to multiply once the crisis is alleviated. The Integrated Cognitive Assessment (ICA), the company’s flagship product and CE-marked medical device software, offers the potential to curtail this backlog before and as it arises, with a 5-minute computerised test of cognitive function that is suitable for remote administration.
Cognetivity is also in conversation with potential customers regarding the use of its wellness app to enable self-monitoring for corporate employees and others whose cognitive and mental health is likely to be negatively affected by their isolation at home.
Hence, the company believes it is well placed to make a positive impact on society and encourage wider uptake of its technology, consistent with its long-standing goals, by empowering clinicians and isolated individuals to cope with the Covid-19 crisis.
All employees are currently working from home in accordance with guidance from the World Health Organization and national health authorities. Cognetivity has established robust practices in the use of remote-working technology to permit meetings to be held with colleagues, collaborators and clients. As such, it expects to continue delivery of its ongoing projects, including an Innovate UK-funded study of the ICA in clinical care at Sussex Partnership NHS Foundation Trust. The company will regularly update its plans to ensure business continuity over the coming months.
Further updates will follow as necessary.
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through ongoing clinical studies to the market in North America, Europe and elsewhere in the world.
For more information, please visit: www.cognetivity.com
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
FORWARD LOOKING STATEMENTS:
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.
The Exchange does not accept responsibility for the adequacy or accuracy of this release
SOURCE Cognetivity Neurosciences Ltd
For further information: Email: email@example.com; For media enquiries contact: Josh Stanbury, Email: firstname.lastname@example.org